We look forward to the European Commission’s decisions.” "EMA CHMP recommends MSD’s KEYTRUDA for gynaecological cancers" was ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Today, the industry leader in wellness technology, Therabody, added five new innovations and four limited editions of bestselling products to their ecosystem of science-backed solutions. The latest ...

TELUS Digital Experience (TELUS Digital) officially launched its global rebrand today, transitioning from TELUS International to TELUS Digital. The new name reflects the company's commitment to ...

This week, Mainz Biomed announced its newest Brand Ambassador, Petra Smeltzer Starke, known serving as General Counsel to the White House Council of Economic Advisors and Senior Advisor to ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer. Patients with high-risk muscle-invasive urothelial ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...